Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share Retweet By
The Effect of Beta Interferon on the Expression of Mir-145 in Patients With Multiple Sclerosis

Summary: A study found beta interferon lowers miR-145 in MS patients, suggesting a treatment biomarker. #MultipleSclerosis #Biomarkers

Ehtesham N1 ; Sharifi M3 ; Khorvash F2 ; Kheirollahi M1
Authors

Source: Journal of Isfahan Medical School Published:2016

Abstract

Background: microRNAs are non-coding RNAs that modulate different types of cellular processes like differentiation and cell death. Hitherto several studies have been done to determine the expression profile of microRNAs in patients with multiple sclerosis (MS) to obtain appropriate biomarkers. In previous studies,it was found that miR-145 was over-expressed. This up-regulation was in patients who did not start taking medicine. Therefore,in this study we assessed the effect of beta interferon on the expression of this microRNA in patients with multiple sclerosis. Methods: We evaluated the expression pattern of miR-145 in 15 patients who did not start taking medicine and called treatment naive,in 15 patients who were under treatment and also 15 healthy people using real-time polymerase chain reaction method. Findings: The expression level of miR-145 in treatment naive patients was 3.9 fold of healthy people (P = 0.005),whereas expression level of this microRNA between healthy people and under treatment patients was not significantly different. Conclusion: Down-regulation of miR-145 in under-treatment patients to the extent of healthy people suggests that probably,this microRNA could be used as predictive biomarker. © 2016,Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
View other Related Docs
1. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
2. Micrornas: Key Modulators of Disease-Modifying Therapies in Multiple Sclerosis : Pancreatic Cancer Is One of the Lethal Malignant Tumours in the World.In This Study, We Investigated the Car T-Cell Therapy of Pancreatic Cancer, International Reviews of Immunology (2020)
3. The Role of Micrornas Involved in the Disorder of Blood–Brain Barrier in the Pathogenesis of Multiple Sclerosis, Frontiers in Immunology (2023)
Experts (# of related papers)
View all Related Experts
Nahid Eskandari (8)
Vahid Shaygannejad (7)
The Effect of Beta Interferon on the Expression of Mir-145 in Patients With Multiple Sclerosis
Other Related Docs
4. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
5. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
6. Microrna-29B Variants and Mxa Expression Change During Interferon Beta Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2019)
7. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
8. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related Micrornas in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2022)
9. Mir-504 Expression Level Is Increased in Multiple Sclerosis Patients Responder to Interferon-Beta, Journal of Neuroimmunology (2020)
10. Investigating the Interaction of Hsa-Mir-193B-5P and Hsa-Circ-Cnot11-0001 in Multiple Sclerosis Disease Through Dual Luciferase Assay, Gene Reports (2025)
11. Analysis of the Expression of Mir-34A, Mir-199A, Mir-30C and Mir-19A in Peripheral Blood Cd4+T Lymphocytes of Relapsing-Remitting Multiple Sclerosis Patients, Gene (2018)
12. Mir-326 and Mir-26A, Two Potential Markers for Diagnosis of Relapse and Remission Phases in Patient With Relapsing-Remitting Multiple Sclerosis, Gene (2014)
13. Microrna-92A Drives Th1 Responses in the Experimental Autoimmune Encephalomyelitis, Inflammation (2019)
14. Upregulation of Cd4+ T-Cell Derived Mir-223 in the Relapsing Phase of Multiple Sclerosis Patients, Cell Journal (2016)
15. Potential Biomarker and Therapeutic Lncrnas in Multiple Sclerosis Through Targeting Memory B Cells, NeuroMolecular Medicine (2020)
16. Genetic Variation in Intergenic and Exonic Mirna Sequence and Risk of Multiple Sclerosis in the Isfahan Patients, Iranian Journal of Allergy, Asthma and Immunology (2018)
17. Study of the Correlation Between Mir-106A, Mir-125B, and Mir-330 on Multiple Sclerosis Patients by Targeting Tnfsf4 and Sp1 in Nf-Κb/Tnf-Α Pathway: A Case-Control Study, Cell Journal (2022)
18. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)
19. An Integrated Bioinformatics Analysis of the Potential Regulatory Effects of Mir-21 on T-Cell Related Target Genes in Multiple Sclerosis, Avicenna Journal of Medical Biotechnology (2021)
20. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)